tesevatinib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
Tesevatinib is an experimental drug proposed for use in kidney cancer and polycystic kidney disease. The drug was first developed by Exelixis, Inc. and was later acquired by Kadmon Corporation. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor, epidermal growth factor receptor 2, vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4).   Wikipedia

Chemistry

  • SMILES: COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]4C[C@@H]5CN(C)C[C@@H]5C4
  • InChIKey: HVXKQKFEHMGHSL-QKDCVEJESA-N
  • Mol. Mass: 491.39
  • ALogP: 5.79
  • ChEMBL Molecule:
    tesevatinib  
More Chemistry

Pharmacology

Alternative names

kd019 | kd-019 | kd-020 | tesevatinib | xl647 | xl-647

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Esophageal Neoplasms (Phase 1)

Glioblastoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Polycystic Kidney, Autosomal Dominant (Phase 2)

Polycystic Kidney, Autosomal Recessive (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue